Literature DB >> 7499287

Cyclic AMP-insensitive activation of c-Src and Syk protein-tyrosine kinases through platelet membrane glycoprotein VI.

T Ichinohe1, H Takayama, Y Ezumi, S Yanagi, H Yamamura, M Okuma.   

Abstract

Platelet glycoprotein (GP) VI is a so-far uncharacterized 62-kDa membrane protein, whose deficiency results in selective impairment in collagen-induced platelet aggregation. Our group previously reported a human polyclonal antibody (anti-p62 IgG) that induces activation of normal, but not of GPVI-deficient, platelets in an Fc-independent manner. The F(ab')2 fragments of this antibody (F(ab')2-anti-p62) stimulated tyrosine phosphorylation of numerous proteins, which was not prevented even in the presence of cAMP-increasing agents such as prostacyclin. Pretreatment of platelets with the protein-tyrosine kinase (PTK) inhibitor tyrphostin A47 completely abolished F(ab')2-anti-p62-induced platelet aggregation in parallel with dose-dependent inhibition of protein-tyrosine phosphorylation, indicating an essential requirement of PTK activity for generating GPVI-mediated signaling. We found that two cytosolic PTKs, c-Src and Syk, became rapidly activated in response to F(ab')2-anti-p62 in a way insensitive to elevation of cAMP. In contrast, in the presence of prostacyclin, F(ab')2-anti-p62 did not stimulate tyrosine phosphorylation of the focal adhesion kinase. cAMP-insensitive activation of c-Src and Syk was also observed in collagen but not thrombin-stimulated platelets. Moreover, either F(ab')2-anti-p62 or collagen stimulated cAMP-insensitive tyrosine phosphorylation of phospholipase C-gamma 2. These results indicate that the receptor-mediated activation of several PTKs in platelets is regulated through a cAMP-sensitive or -insensitive mechanism depending on the nature of each stimulus, and also suggest that GPVI engagement is coupled to cAMP-insensitive activation of c-Src and Syk accompanied by tyrosine phosphorylation of numerous substrates including phospholipase C-gamma 2 in a manner similar to collagen stimulation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7499287     DOI: 10.1074/jbc.270.47.28029

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Inhibition of human platelet adenylate cyclase activity by adrenaline, thrombin and collagen: analysis and reinterpretation of experimental data.

Authors:  A Juska; R W Farndale
Journal:  Biochem J       Date:  1999-05-15       Impact factor: 3.857

2.  Role of phosphoinositide 3-kinase beta in glycoprotein VI-mediated Akt activation in platelets.

Authors:  Soochong Kim; Pierre Mangin; Carol Dangelmaier; Rivka Lillian; Shaun P Jackson; James L Daniel; Satya P Kunapuli
Journal:  J Biol Chem       Date:  2009-08-21       Impact factor: 5.157

3.  Trophoblast adhesion of the peri-implantation mouse blastocyst is regulated by integrin signaling that targets phospholipase C.

Authors:  Jun Wang; Linda Mayernik; D Randall Armant
Journal:  Dev Biol       Date:  2006-09-14       Impact factor: 3.582

4.  Protein-tyrosine-kinase-dependent expression of cyclo-oxygenase-1 and -2 mRNAs in human endothelial cells.

Authors:  K Hirai; H Takayama; K Tomo; M Okuma
Journal:  Biochem J       Date:  1997-03-01       Impact factor: 3.857

5.  A novel antiplatelet antibody therapy that induces cAMP-dependent endocytosis of the GPVI/Fc receptor gamma-chain complex.

Authors:  Hiroshi Takayama; Yoshitaka Hosaka; Kazuyuki Nakayama; Kamon Shirakawa; Katsuki Naitoh; Tomokazu Matsusue; Mikihiko Shinozaki; Motoyasu Honda; Yukiko Yatagai; Tetsushi Kawahara; Jiro Hirose; Tooru Yokoyama; Michiru Kurihara; Shoji Furusako
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

6.  Physical and functional association of the Src family kinases Fyn and Lyn with the collagen receptor glycoprotein VI-Fc receptor gamma chain complex on human platelets.

Authors:  Y Ezumi; K Shindoh; M Tsuji; H Takayama
Journal:  J Exp Med       Date:  1998-07-20       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.